دورية أكاديمية
أعرض في EDS

Interleukin-9 in Immunopathology of Trypanosoma cruzi Experimental Infection.

التفاصيل البيبلوغرافية
العنوان: Interleukin-9 in Immunopathology of Trypanosoma cruzi Experimental Infection.
المؤلفون: Silva NSL; Microbiology, Immunology and Parasitology Department, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil., Orikaza CM; Microbiology, Immunology and Parasitology Department, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil., de Santana FR; Microbiology, Immunology and Parasitology Department, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil., Dos Santos LA; Microbiology, Immunology and Parasitology Department, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil., Salu BR; Biochemistry Department, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil., Oliva MLV; Biochemistry Department, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil., Sinigaglia RC; Electronic Microscopy Center, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil., Mortara RA; Microbiology, Immunology and Parasitology Department, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil.
المصدر: Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2021 Oct 15; Vol. 11, pp. 756521. Date of Electronic Publication: 2021 Oct 15 (Print Publication: 2021).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Media SA
مواضيع طبية MeSH: Chagas Disease* , Interleukin-9* , Trypanosoma cruzi*, Animals ; Cytokines ; Humans ; Mice ; Mice, Inbred BALB C
مستخلص: Chagas' disease is a parasitosis caused by Trypanosoma cruzi , which affects approximately 8 million people worldwide. The balance between pro- and anti-inflammatory cytokines produced during immunological responses contributes to disease prognosis and progression. Parasite tissue persistence can induce chronic inflammatory stimuli, which can cause long-term tissue injury and fibrosis. Chronic Chagas' patients exhibit increased levels of interleukin (IL)-9, an important cytokine in the regulation of inflammatory and fibrogenic processes. Data on the role of IL-9 in other pathologies are sometimes contradictory, and few studies have explored this cytokine's influence in Chagas' disease pathology. Hence, the aim of this study was to evaluate the role of IL-9 in the progression of T. cruzi infection in vivo and in vitro . In vitro infection demonstrated that IL-9 reduced the number of infected cells and decreased the multiplication of intracellular amastigotes in both C2C12 myoblasts and bone marrow-derived macrophages. In myoblasts, the increased production of nitric oxide (NO) was essential for reduced parasite multiplication, whereas macrophage responses resulted in increased IL-6 and reduced TGF-β levels, indicating that parasite growth restriction mechanisms induced by IL-9 were cell-type specific. Experimental infection of BALB/c mice with T. cruzi trypomastigotes of the Y strain implicated a major role of IL-9 during the chronic phase, as increased Th9 and Tc9 cells were detected among splenocytes; higher levels of IL-9 in these cell populations and increased cardiac IL-9 levels were detected compared to those of uninfected mice. Moreover, rIL9 treatment decreased serum IL-12, IL-6, and IL-10 levels and cardiac TNF-α levels, possibly attempting to control the inflammatory response. IL-9 neutralization increased cardiac fibrosis, synthesis of collagens I and III, and mastocyte recruitment in BALB/c heart tissue during the chronic phase. In conclusion, our data showed that IL-9 reduced the invasion and multiplication of T. cruzi in vitro , in both myoblasts and macrophages, favoring disease control through cell-specific mechanisms. In vivo , IL-9 was elevated during experimental chronic infection in BALB/c mice, and this cytokine played a protective role in the immunopathological response during this phase by controlling cardiac fibrosis and proinflammatory cytokine production.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Silva, Orikaza, Santana, dos Santos, Salu, Oliva, Sinigaglia and Mortara.)
References: J Biol Regul Homeost Agents. 2012 Jul-Sep;26(3):319-26. (PMID: 23034251)
J Immunol. 2007 Aug 15;179(4):2051-4. (PMID: 17675461)
PLoS One. 2012;7(3):e33271. (PMID: 22413008)
Annu Rev Pathol. 2019 Jan 24;14:421-447. (PMID: 30355152)
PLoS Negl Trop Dis. 2011;5(5):e992. (PMID: 21655351)
Clin Chem Lab Med. 2013 Feb;51(2):271-94. (PMID: 23045386)
Biomed Rep. 2017 Jun;6(6):633-639. (PMID: 28584634)
J Biol Chem. 1994 Nov 4;269(44):27580-8. (PMID: 7525557)
Parasitol Res. 2016 Feb;115(2):779-85. (PMID: 26526953)
Front Cell Infect Microbiol. 2020 Jan 28;10:5. (PMID: 32117793)
Cell Immunol. 1999 Apr 10;193(1):90-8. (PMID: 10202116)
Nature. 2010 Jun 24;465(7301):S6-7. (PMID: 20571554)
Semin Immunopathol. 2017 Jan;39(1):29-38. (PMID: 27900450)
Microbes Infect. 2008 Apr;10(5):540-7. (PMID: 18403242)
Elife. 2018 Mar 26;7:. (PMID: 29578409)
PLoS One. 2014 Mar 06;9(3):e87082. (PMID: 24603474)
Clin Immunol Immunopathol. 1997 May;83(2):165-72. (PMID: 9143377)
Front Immunol. 2020 Jun 05;11:1010. (PMID: 32655546)
Cancer Lett. 2002 Jan 25;175(2):181-5. (PMID: 11741746)
Rev Esp Cardiol. 2006 Jan;59(1):50-6. (PMID: 16434004)
Acta Trop. 2016 May;157:42-53. (PMID: 26827742)
Mediators Inflamm. 2014;2014:683230. (PMID: 25210230)
Circulation. 1999 Jun 29;99(25):3260-5. (PMID: 10385500)
Circ Res. 2005 Aug 19;97(4):380-90. (PMID: 16037568)
Int J Cardiol. 2005 Mar 18;99(2):233-7. (PMID: 15749181)
Clin Dev Immunol. 2012;2012:361730. (PMID: 22811738)
PLoS Negl Trop Dis. 2016 Apr 26;10(4):e0004669. (PMID: 27115869)
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12885-90. (PMID: 19433802)
BMC Infect Dis. 2017 Mar 21;17(1):221. (PMID: 28327099)
Am J Pathol. 2001 Aug;159(2):703-9. (PMID: 11485928)
PLoS Negl Trop Dis. 2010 Jun 15;4(6):e711. (PMID: 20559542)
J Immunol Res. 2015;2015:895416. (PMID: 26509179)
Cytokine. 2015 Jul;74(1):62-8. (PMID: 25649043)
Eur J Immunol. 2017 Sep;47(9):1513-1524. (PMID: 28665005)
Infect Immun. 1996 Jan;64(1):128-34. (PMID: 8557330)
Sci Rep. 2016 Jan 05;6:18694. (PMID: 26728971)
BMC Infect Dis. 2012 May 24;12:123. (PMID: 22625224)
Science. 1992 Jul 17;257(5068):387-9. (PMID: 1631560)
Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:208-18. (PMID: 19753476)
Cancer Res. 2014 Dec 1;74(23):6845-55. (PMID: 25297635)
Life Sci. 2020 Oct 1;258:118137. (PMID: 32712299)
Autoimmun Rev. 2011 Jan;10(3):163-5. (PMID: 20883825)
Inflammation. 2019 Aug;42(4):1360-1369. (PMID: 30887397)
Circulation. 2007 Mar 20;115(11):1398-407. (PMID: 17353445)
PLoS One. 2014 Mar 07;9(3):e91154. (PMID: 24608170)
PLoS Negl Trop Dis. 2015 Aug 25;9(8):e0004025. (PMID: 26305786)
Front Microbiol. 2018 Mar 26;9:553. (PMID: 29662478)
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2265-70. (PMID: 24469818)
Parasite Immunol. 2019 Oct;41(10):e12663. (PMID: 31309590)
J Neuroimmunol. 2011 Jun;235(1-2):84-90. (PMID: 21496931)
Science. 2017 Jun 9;356(6342):1072-1076. (PMID: 28495875)
J Immunol. 2000 Jun 15;164(12):6166-73. (PMID: 10843666)
Int J Parasitol. 2002 Feb;32(2):167-70. (PMID: 11812493)
Front Immunol. 2018 Apr 27;9:896. (PMID: 29755471)
Front Immunol. 2019 Mar 28;10:580. (PMID: 31001246)
Immunol Lett. 1998 Aug;63(1):1-8. (PMID: 9719432)
Circulation. 2004 Nov 16;110(20):3221-8. (PMID: 15533863)
Infect Immun. 2003 Mar;71(3):1225-33. (PMID: 12595436)
Front Immunol. 2016 Oct 06;7:409. (PMID: 27766098)
J Mol Cell Cardiol. 2011 Oct;51(4):600-6. (PMID: 21059352)
J Clin Invest. 2009 Nov;119(11):3213-25. (PMID: 19855130)
J Immunol. 2011 Jan 1;186(1):83-91. (PMID: 21115728)
Antimicrob Agents Chemother. 2014 Oct;58(10):6157-64. (PMID: 25092706)
Infect Immun. 2002 Sep;70(9):5115-23. (PMID: 12183561)
Clin Pharmacol Ther. 2012 Nov;92(5):613-21. (PMID: 22990752)
Braz J Med Biol Res. 1998 Jan;31(1):127-31. (PMID: 9686189)
Circulation. 2000 Dec 12;102(24):3003-8. (PMID: 11113053)
PLoS Pathog. 2016 Oct 3;12(10):e1005902. (PMID: 27695083)
J Immunol. 2011 Mar 15;186(6):3283-8. (PMID: 21368237)
J Immunol. 2005 Feb 15;174(4):2205-11. (PMID: 15699153)
Int J Cell Biol. 2010;2010:. (PMID: 20811486)
Mem Inst Oswaldo Cruz. 1999;94 Suppl 1:253-5. (PMID: 10677728)
Front Immunol. 2018 Aug 24;9:1929. (PMID: 30197647)
Hypertension. 2010 Aug;56(2):225-31. (PMID: 20606113)
فهرسة مساهمة: Keywords: IL-9; Th9; Trypanosoma cruzi; collagen; fibrosis
المشرفين على المادة: 0 (Cytokines)
0 (Interleukin-9)
تواريخ الأحداث: Date Created: 20211101 Date Completed: 20211125 Latest Revision: 20220531
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8554238
DOI: 10.3389/fcimb.2021.756521
PMID: 34722343
قاعدة البيانات: MEDLINE
الوصف
تدمد:2235-2988
DOI:10.3389/fcimb.2021.756521